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To cap it all off, again: dynamic capping and recapping of coding and 
non-coding RNAs to control transcript fate and biological activity
KLB Borden a, B Culjkovic-Kraljacica, and VH Cowlingb
aDepartment of Pathology and Cell Biology, Institute of Research in Immunology and Cancer, University of Montreal, Montreal, Canada; 
bCentre for Gene Regulation and Expression, School of Life Sciences, University of Dundee, Dundee, UK, UK
ABSTRACT
The addition of the methyl-7-guanosine (m7G) “cap” on the 5' ends of coding and some non- 
coding RNAs is essential for their protein coding capacity and biochemical activity, respectively. It 
was previously considered that capping was a constitutive process that generates a complete cap 
on all transcripts at steady-state. However, development of new methodologies demonstrated 
that steady-state capping is a dynamic and regulatable feature of many coding and non-coding 
RNAs. Indeed, capping status of specific RNAs can flux during differentiation and development, 
thereby impacting on their protein-coding capacity and activity. Moreover, in some primary 
cancer specimens, capping can be elevated for transcripts encoding proteins involved in prolif-
eration and survival corresponding to their increased protein levels. Overexpression of one of the 
capping enzymes (RNMT), the transcription factor MYC or the eukaryotic translation initiation 
factor eIF4E all led to increased levels of steady-state capping of selected transcripts. Additionally, 
transcripts can be decapped and recapped, allowing these to be sequestered until needed. This 
review provides a summary of the major advances in enzymatic and affinity-based approaches to 
quantify m7G capping. Further, we summarize the evidence for regulation of capping. Capping 
has emerged as a significant regulatory step in RNA metabolism which is poised to impact 
a myriad of biological processes.
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Methyl-7 guanosine (m7G) “cap” addition to 
the 5' end of coding RNAs and many non- 
coding transcripts impacts virtually all levels 
of their processing, which in turn, influences 
the capacity for coding RNAs to be translated 
into protein and the biochemical activity of 
non-coding RNAs [1–3]. For many years, cap-
ping was widely regarded as a constitutive 
property with the expectation that 100% of 
coding RNAs would be capped. Over the last 
20 years, it has become evident 
that m7G capping is not simply a default house-
keeping process, but rather is a highly regulated 
step in RNA processing that impacts on the 
biochemical functions of many transcripts [2– 
10]. These new findings indicate that the extent 
of capping for a given RNA population varies 
and this is influenced by development, differ-
entiation or oncogene expression [7,9,11–13]. 
Moreover, once capped, RNAs can be decapped 
and then recapped [4,6,14]. In this way, cap 
removal does not inextricably lead to RNA 
decay. This has led to the notion of cap home-
ostasis, whereby the cap status of transcripts 
can be regulated to impact RNA export, trans-
lation, stability etc [4]. Consistent with this 
model, genome-wide studies suggest that 
uncapped RNAs are more stable than antici-
pated and in this way, cap status can be 
a means to titrate transcript activity as well as 
capacity to undergo other processing steps. 
Here, we review the consequences of dynamic 
capping and mechanisms involved in modulat-
ing this pathway. This review focusses 
on m7G capping, but there are other types of 
caps and these will be discussed briefly (Figure 
1). This review describes the RNA biochemistry 
related to capping, recent methodological 
advances to measure m7G capping and the bio-
logical impact of regulating capping.
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Diversity in RNA caps
Here, we focus on the m7G cap at the 5' end of 
transcripts (Figure 1). This is characterized by 
a 5'-5' pyrophosphate bond linking the m7G to 
the first transcribed nucleotide on the 5' end of 
the transcript [1]. Many of the methods used to 
quantify capping will capture variants of 
this m7GpppX form because they are based on 
identifying 5'-5' pyrophosphate linkages. 
Examples of these would include unmethylated 
guanosine caps as well as trimethylated (TMG) 
caps which are methylated at positions 2, 2 and 
7 on the guanosine ring (Figure 1). The m7G cap, 
with only one methyl group on the 5' guanosine, 
is also referred to as Cap-0 (Figure 1). RNAs can 
also be methylated at the 2' hydroxyl of the first 
transcribed nucleotide ribose referred to as Cap-1 
(m7GpppXm) and on the same position in 
the second transcribed nucleotide ribose which 
is referred to as Cap-2 (m7GpppXmXm) [1]. In 
addition, more chemically diverse caps have been 
identified. For instance, NAD substitutes for 
the m7G cap on some transcripts, particularly 
mitochondrial RNAs [15] (Figure 1). Plant viruses 
may have unique caps made of protein, as 
observed for the potyvirus protein genome linked 
(VPg) that is covalently attached to the 5' end of 
potyviral genomic RNA [16]. Structural studies 
indicate that VPg directly binds to the cap- 
binding site of the eukaryotic translation 
Figure 1. Chemical structures of different forms of 5' RNA caps. The methylation or NAD modifications are highlighted by blue 
circles. Only cap-types described in the text are shown. Thus, this is not an exhaustive list of cap types.
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initiation factor eIF4E and can recruit RNAs to 
the translation machinery via this interaction 
[16]. Thus, potyvirus VPg engages eIF4E in 
a manner similar to the m7G cap in vitro. 
Whether other protein-RNA conjugates can simi-
larly engage eIF4E for RNA export or translation 
remains to be examined. Also, it has been sug-
gested that some coding RNAs could be TMG 
capped (Figure 1), instead of m7G capped, similar 
to what is observed in nematode TMG mRNAs or 
human UsnRNAs [17–19]. In this form, some 
TMG capped coding RNAs are able to bind 
eIF4E and undergo translation, as is routine in 
nematodes.
Enzymology of m7G Capping
Capping is a three-step process involving RNGTT 
(RNA guanylyltransferase and 5' phosphatase) and 
RNMT (RNA guanine-7- methyltransferase) [20] in 
mammals (Figure 2). These enzymes are required for 
capping and cell survival [2,21–27]. RNGTT removes 
the 5' phosphate of the 5' triphosphate on the pre- 
mRNA or non-coding RNA using its 5' phosphatase 
activity [28]. This produces a 5'-diphosphate-RNA 
which then serves as a RNGTT substrate for addition 
of guanosine monophosphate via a distinct 5'-5' pyr-
ophosphate linkage. The cap guanylate is then methy-
lated by RNMT, the only enzyme known to carry out 
this modification [2]. To do this, it uses its methyl-
transferase domain and S-adenosyl methionine (SAM) 
as the methyl donor [29,30]. RNMT also binds RAM, 
a small protein co-factor which increases its methyla-
tion activity and can recruit RNAs to the complex [29]. 
At steady state, localization of RNMT and RNGTT is 
mainly nuclear; however, these factors have also been 
identified in the cytoplasm suggesting that capping can 
occur in either compartment [6,23,31]. In this way, 
RNAs that are decapped are not always fated to be 
degraded [32]. Further, while capping is generally con-
sidered to be co-transcriptional, the cytoplasmic loca-
lization of these enzymes and the observation of re- 
capping activity in that compartment suggest that re- 
capping could also occur independent of transcription 
(discussed in Recapping of RNAs after Decapping 
section below). Thus, like splicing and polyadenylation 
[33–35], it appears that capping can occur both co- and 
post-transcriptionally.
Methods to monitor m7G capping of specific 
transcripts at steady-state
The m7G cap was first identified in viral RNA. In the 
1970s, caps were detected by mass spectrometry by 
digestion and radiolabelling of mRNA [1,36–40]. 
More recently, advanced nucleotide purification meth-
odologies have resulted in rapid mass spectrometry cap 
analysis of relatively small samples of RNA, including 
using a method called CAP-MAP [41,42]. This allows 
quantitation of different cap structures. Cap modifica-
tions have also been detected by resolving radiolabelled 
nucleotides using two-dimensional thin-layer chroma-
tography (TLC) [43]. These methods of bulk RNA cap 
quantitation are complimentary to single gene 
approaches described below. These mass spectrometry 
approaches have proved invaluable in confirming the 
impact of genetic targeting of capping enzymes in cell 
lines and organisms [44].
The development of methodologies to accurately 
quantify steady-state capping levels on a per transcript 
basis has provided major new insights into capping 
and evidence to support the concept of cap home-
ostasis and dynamic capping. Some methods can 
quantify fold changes in capping for a given RNA 
species; while others can provide the percentage 
of m7G- or G-capped and/or uncapped RNAs. The 
approaches can be roughly divided into affinity-based 
or enzymatic methods (Table 1). Both strategies iden-
tify the RNAs in question using RNA-Seq or RT-qPCR 
and for older studies, microarrays. Importantly, the 
approaches differ in the form of cap or uncapped 
RNAs detected with some approaches offering more 
general applicability than others. These approaches are 
summarized in Table 1.
Affinity methods developed to date capture RNAs 
with an m7G group, regardless of methylation at other 
positions of the cap. These measure steady-state cap-
ping and include immunoprecipitation (IP) with anti- 
m7G cap antibodies in a method known as CapIP or 
employ pulldown approaches with purified eIF4E, 
an m7G cap-binding protein [6,9,11,45–47]. To ensure 
that RNA secondary structure or RNA binding factors 
do not interfere with binding to the antibody or to 
eIF4E, both approaches are performed using purified 
RNA isolated from cells rather than carrying out stu-
dies directly from cell lysates [9,29,48]m7G cap anti-
bodies can also recognize TMG caps. Thus, it is 
important to distinguish if RNAs are m7G capped 
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Figure 2. Biochemical pathways for m7G RNA capping. Capping is completed by two enzymes in mammals, RNGTT carries out the 
removal of the 5' phosphate (Step 1) and subsequent addition of the guanosine via the unique 5'-5' pyrophosphate linage (Step 2). 
This G-capped RNA is now a substrate for the RNMT, which uses SAM as the methyl donor to generate m7G capped RNA and 
S-adenosyl homocysteine (SAH). Additional methylation events depicted in Figure 1 are carried out by other enzymes and not 
described here.
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Table 1. Methods to study capping on a per RNA basis.
Methods Description Types of RNAs identified References
CapIP (normal) Using an anti-m7G cap antibody to 
identify m7G capped RNAs
RNAs that have m7G or with less affinity TMG caps. 
Addition of m7GpppG competition can 
demonstrate m7G specificity
Cowling and Cole, 2007; Cole and 
Cowling, 2009; Bochnig et al, 1987; 
Moteki and Price, 2002 [10,48,73,74]
CapIP 
(quantitative)
RNAs and amount of anti- 
m7G antibody are carefully titrated 
to quantitatively immunoprecipitate 
transcripts with parallel analysis of 
supernatants to monitor depletion 
of RNAs to assess percent capping
RNAs that have m7G or with less affinity TMG caps. 
Addition of m7GpppG competition can 
demonstrate m7G specificity
CulljkovicKraljacic et al, 2020 [9]
CapTure/eIF4E 
pulldown
Pulldown with the cap-binding 
protein eIF4E. Purified eIF4E protein 
is immobilized on a solid support 
(such as GST-eIF4E on glutathione 
beads), and purified RNAs 
incubated with the resin (and with 
a negative control such as GST). In 
CapTure, an eIF4E mutant that 
binds the m7G cap more tightly (the 
eIF4E K119A mutant) is used for 
more efficient capture of 
transcripts. Human eIF4E can bind 
to TMG and G-capped transcripts 
albeit with much lower affinity. 
Competition assays with m7GpppG 
is important for validating 
interactions are m7G dependent.
m7G RNAs, with potential for weak binding to TMG 
and/or G-capped RNAs




Enzymatic method using alkaline 
phosphatase (AP) leading to OH- 
groups on the 5‘ end of uncapped 
RNAs followed by tobacco acid 
pyrophosphatase (TAP) leaving a 5‘ 
monophosphate which is then 
ligated to a biotinylated 
oligonucleotide to isolate capped 
RNAs for analysis. In parallel, total 
RNA levels are monitored using 
TAP, AP and PNK. In this way 
percentages of capped RNAs can be 
directly calculated on a per RNA 
basis or coupled with RNA-Seq
RNAs with a 5’-5’ pyrophosphate bond (e.g. m7G, 
G, NAD, TMG)
Culljkovic-Kraljacic et al, 2020 [9]
Oligocapping AP removes 5‘ phosphatases of 
non-capped RNAs followed by TAP 
to remove pyrophosphate leaving 
a 5‘ monophosphate used for 
ligation. To identify RNAs, the 
ligated oligonucleotide provides the 
5' primer and the 3‘ primer is used 
to quantitate the gene of interest 
by RT-qPCR
RNAs with a 5‘  pyrophosphate bond (m7G, G, TMG, 
NAD, other).
Maruyama and Sugano 1994 [50]
CapSMART Switching Mechanism at the 5' end of 
RNA Transcripts (SMART): AP to leave 
OH on uncapped RNAs, with PNK to 
add single 5‘ phosphate on previously 
uncapped RNAs which are then 
ligated to STOP oligonucleotides to 
block template switching. Then 
capped RNAs are captured
RNAs with a 5‘  pyrophosphate bond (m7G, G, TMG, 
NAD, other)
Machida and Lin, 2014 [49]
NonCapSMART RNAs were treated with AP, followed 
by TAP leaving 5‘ phosphates on the 
RNAs that were capped and 5‘ OH on 
the RNAs that were not capped. STOP 
oligonucleotides are ligated onto the 
previously capped RNAs to block 
template switching while uncapped 
RNAs captured using template 
switching.
Uncapped RNAs (RNAs without a 5'pyrophosphate) Machida and Lin 2014 [49]
(Continued )
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rather than TMG capped. For this purpose, competi-
tion with m7G cap analogs ensure RNAs 
are m7G capped and in parallel competition with 
GpppG, ensures that RNAs are indeed methylated 
(GpppG will not compete for m7G capped RNAs) 
[9]. Depletion of RNA bound to anti-m7G cap anti-
body after m7G cap analog treatment provides strong 
evidence that the RNA target is m7G capped. While 
CapIP readily reveals changes in capping fold between 
two conditions [9,11,46], it is challenging to 
obtain percent occupancy of caps on a per transcript 
basis. Despite this limitation, many coding and non- 
coding RNAs were found to be regulated at the level of 
capping using this method [11,46]. Affinity approaches 
based on eIF4E RNA pulldowns of purified transcripts 
have also been employed. These utilize either purified 
wildtype eIF4E or the K119A eIF4E mutant protein. 
The K119A mutant has a higher m7G-cap affinity than 
wildtype eIF4E and thus is utilized to capture RNAs 
with increased efficiency [6,45]. This latter method is 
referred to as CapTure [28]. These methods reveal 
differences in fold of capping between conditions.
Quantitative CapIP methods have also been 
developed [9]. These methods rely on the determi-
nation of quantitative conditions optimizing dif-
ferent ratios of anti-m7G cap antibodies to purified 
RNA to establish conditions for maximal capture 
of m7G capped transcripts. These results are com-
pared to the amount of RNA bound to IgG beads 
to establish the background binding. For the same 
samples, RNAs are monitored in the supernatant 
(SN) fractions of the CapIP and IgG IP. In parallel 
aliquots, IPs are performed in the presence of high 
levels of m7GpppG (relative to GpppG) to ensure 
specificity of the anti-m7G antibody. To obtain 
percentage of RNAs that are capped, levels of 
specific RNAs are quantified from the superna-
tants of the CapIP (Cap-SN) or Ctrl-IPs (Ctrl- 
SN) by RT-qPCR. Depletion of the RNA from 
the supernatant indicates RNAs are bound in the 
IP. Ctrl-IPs are comprised of CapIP in the pre-
sence of 100 μM m7GpppG to validate specificity 
and ascertain if RNAs are binding nonspecifically 
to the antibodies or beads. The ratio of Cap-SN to 
Ctrl-SN gives the percentage of uncapped RNAs. 
This can then be converted to a percentage of 
capped RNA. This method can be applied to dif-
ferent conditions to ascertain how percentages of 
capping change for candidate RNAs.
Enzymatic and chemical methods have also 
been used to quantify the extent of capping and 
can be readily coupled to RNA-sequencing tech-
nologies (Table 1). One such method is referred to 
as Cap Quantitation (CapQ) which relies on the 
unique sensitivity of capped RNAs to tobacco acid 
pyrophosphatase (TAP) [9] and their insensitivity 
to Alkaline Phosphatase (AP). In a mixture of 
capped and uncapped RNAs, AP leads to removal 
of 5'-phosphates on uncapped RNAs and replace-
ment by 5' OH groups, but does not affect capped 
RNAs. Subsequent treatment with TAP will cleave 
any pyrophosphate bond and thus cleave m7G or 
G capped RNAs leaving a 5' monophosphate, but 
not alter the 5'OH RNAs originating from the 
Table 1. (Continued). 
Methods Description Types of RNAs identified References
XRN sensitivity 
assays
XRN is a 5' to 3' nuclease that will 
degrade RNAs that are not capped
Uncapped RNAs (those without a 5'-5' 
pyrophosphate linkage: m7G, G, TMG, NAD, etc)
Mukherjee et al, 2012 [14]
RLM 5'RACE Uncapped RNAs have 5' phosphate 
that is ligated to an adaptor that is 
subsequently hybridized to 
complementary biotinylated 
adaptor which allowed isolation of 
only not capped RNAs
Uncapped RNAs Jiao et al., 2008 [7]
Cap Trapper Biotinylation of diol residues (5' cap 
structure and 3' terminal 
nucleotide)
RNAs with a 5‘-5'pyrophosphate (e.g. m7G, G, TMG, 
NAD)
Carninci et al 1996 [51]




Original CAGE used CapTrapper for 
finding 5' ends, and olido-dT 
primers for synthesizing cDNAs [52]. 
Later incarnations of this method 
with template switching are no 
longer cap-specific for the 5' end.
RNAs with a 5‘-5'pyrophosphate (e.g. m7G, G, TMG, 
NAD)
Shiraki et al 2003 [52]; 
Kodzius et al, 2006 [54]
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uncapped population. Thus, when AP treatment is 
followed by TAP, the capped RNAs are converted 
to transcripts with a 5'-monophosphate which can 
be ligated to biotinylated primers, isolated and 
analyzed by RT-qPCR or RNA-Seq. The RNAs 
with 5'OH groups remain, and cannot be ligated 
to biotinylated primers and thus are not captured. 
To obtain total levels of RNAs, separate aliquots of 
the same samples are treated with AP and TAP 
followed by polynucleotide kinase (PNK) which 
leaves all RNAs, independently of their initial 5' 
end status, with a 5'-monophosphate group suita-
ble for ligation with biotinylated oligonucleotides. 
In this way, the amount of capped and total RNA 
can be obtained from the same sample allowing 
a calculation of percent capping on a per transcript 
basis.
CapQ is derived from the Oligo-Capping and 
Ligation method which similarly utilize AP and 
TAP to identify capped RNAs [49,50]; but CapQ 
offers several advantages including calculation 
of percent of capped RNAs since total RNAs are 
also calculated from the same sample. 
Modification of a method referred to as SMART 
(Switching Mechanism at 5' end of RNA 
Transcript) allows selection of capped 
(CapSMART) or of RNAs without the m7G cap 
(Non-CapSMART) [49]. For Non-CapSMART, 
RNAs are treated with AP and TAP which leaves 
only the capped RNAs with a 5'-monophosphate, 
these are then ligated to stop oligonucleotides to 
block template switching. For CapSMART, AP and 
PNK are used to obtain 5'-monophosphates on 
uncapped RNA which are then ligated to stop 
oligonucleotides to inhibit template switching, 
and thus only capped RNAs are observed. 
Another approach is RNA ligase mediated 5' 
rapid amplification of cDNA ends (RLM-RACE) 
which allows detection of uncapped RNAs by liga-
tion to a primer to the 5'-monophosphate on 
uncapped RNAs [7]. Chemical methods have also 
been used including CapTrapper whereby the diols 
on the 5' and 3' ends of the transcripts are oxidized 
and biotinylated for capture and isolation [51]. 
CapTrapper was incorporated into the original 
CAGE protocols [52], which have since evolved 
to a template switching modality, and thus more 
recent CAGE methods do not specifically capture 
capped RNAs [53,54]. Another strategy leverages 
XRN, a nuclease which degrades uncapped RNAs 
but not RNAs with a 5' pyrophosphate bond [14]. 
A comparison of the XRN sensitive and insensitive 
populations reveals RNAs that are uncapped [14]. 
These methods are readily amenable to RNA-Seq 
and indeed such studies have revealed dynamics in 
the population of capped RNAs [7].
m7G capping as a dynamic property of both 
coding and non-coding RNAs
Until recently, formation of the m7G cap was 
considered to be a constitutive property that pro-
duced 100% correctly capped transcripts; and con-
versely, decapping inevitably led to RNA decay [1]. 
However, recent studies, using the methodologies 
described above, indicate that capping is dynamic 
with different RNA populations preferentially 
capped and others that are incorrectly capped 
[2,5,7,9,10]. In other words, if there are 100 tran-
scripts of CCND1 RNAs, not the entire population 
will have a m7G cap [11,47]. About 10 years ago, 
studies demonstrated that impaired capping could 
act as an RNA surveillance mechanism [5]. The 
most common capping error identified was non- 
methylation at the 7 position of the 5' guanosine 
[5]. Stressing the relevance of this, there are cellu-
lar mechanisms in place to specifically remove 
RNAs without methylated caps [5]. However, pre-
ferential and dynamic capping of certain popula-
tions of RNAs has been observed in plant and 
animal cells [7,9,12,14,46,48]. In this case, it 
appears a regulatory modality rather than 
a malfunction of the capping machinery.
About 15 years ago, a landmark study reported 
substantial uncapped RNA populations in 
Arabidopsis thaliana [7]. To study capping, this 
group developed the RLM-RACE method (described 
above) which allowed T4 RNA ligase to ligate an 
oligonucleotide to the 5'-monophosphate on RNAs 
[7]. This will capture RNAs with a 5'-monopho-
sphate but not m7G or G-capped RNAs with a 5'-5' 
pyrophosphate linkage. RNAs were identified by 
microarray analysis. More than 90% of expressed 
genes had some uncapped RNAs identified; how-
ever, the relative percentage of uncapped to capped 
RNAs differed based on the transcript examined. 
Between ~500 to 1000 RNAs were enriched in their 
uncapped forms. Capping fluxed in a transcript- 
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specific manner through developmental stages. 
Intriguingly, ~2-3% of RNAs were only identified 
in the uncapped form [7]. These studies also discov-
ered the first RNA elements that were linked to 
increased abundance of uncapped RNAs. In this 
case, uncapped RNAs were enriched in the presence 
of specific versions of AU-rich elements or with 
sORFs. Also, transcripts enriched in the uncapped 
form tended to be longer (more than 1000 nucleo-
tides) and contain more introns [7].
To directly monitor the m7G capped RNA 
population, CapIP methods were employed to 
monitor the enrichment of capped RNAs in 
mammalian cells [9,11,46,48]. In this case, the 
anti-m7G cap antibody will capture RNAs that 
have a m7G cap, and thus G-capped RNAs, 
despite their 5'-5' pyrophosphate linkage, would 
not be detected as “capped” potentially yielding 
a population different than the RLM 5'RACE 
method above. Further, these studies provide 
fold changes in capping on a per transcript basis 
using PCR strategies [11,46]. These studies 
revealed that MYC overexpression could elevate 
relative capping of many of its own transcrip-
tional targets, for example, CCND1, Fbl, eIF2B1 
and eIF4A1 [46]. Direct elevation of the capping 
machinery through RNMT overexpression 
increased capping of several of these same targets 
as well increased capping of ~3-fold for MYC 
[46]. Importantly, even though RNMT is part of 
the general capping machinery, the capping of all 
RNAs examined was not enhanced (e.g. GAPDH) 
characteristic of the specificity of this process. 
Moreover, increases in capping were normalized 
to total RNA levels, that is, increased capping was 
not simply a reflection of increased RNA levels.
The development of other methods allowed 
quantitative assessment of capping on a per-RNA 
basis as a function of eIF4E dysregulation. eIF4E is 
associated with many aggressive cancers [55]. 
eIF4E acts as a m7G cap chaperone for many 
RNAs and is involved in translation, RNA export 
and 3'end processing [56–59]. Both quantitative 
CapIP methods and in parallel, Cap quantitation 
(CapQ) approaches, were used to measure cap-
ping. These studies revealed that many RNA 
populations were much less capped at steady- 
state in vector control cells than anticipated. 
Indeed, ~30-50% of RNAs (CCND1, MYC, 
Mdm2, Fbl, eIF4A1, eIF2B1 and non-coding 
RNAs MALAT and NEAT) were capped and 
even RNAs that are not regulated by eIF4E, for 
example, ACTNB, were only 50–70% capped at 
steady-state [9]. eIF4E overexpression, at least in 
part through its ability to drive expression of the 
capping machinery, elevated capping of subset of 
RNAs (Mdm2, CTNNB1, MALAT, NEAT, MYC, 
CCND1) to 60–100% depending on the specific 
RNA but did not alter other targets such as 
ACTNB. In support of these findings, quantitative 
CapIP (which depends on the presence of 
the m7G) and CapQ (which will identify any 
RNAs with a 5'-5'pyrophosphate linkage) yielded 
highly concordant results. Combining CapIP with 
RNA-Seq led to the revelation that eIF4E impacted 
the capping of 100s of coding and non-coding 
RNAs including long non-coding RNAs such as 
ABALON, AC006116.27 and AC006116.24. eIF4E 
led to increased capping of some RNAs and 
reduced capping of others. This suggests that 
there is a competition for limited resources 
(RNGTT, RAM, RNMT, SAM) whereby eIF4E 
tips the balance to favor specific transcripts. 
eIF4E required RNMT for its effects on capping 
and there was substantial overlap between eIF4E 
and RNMT capping targets. For example, eIF4E, 
like RNMT, also elevated capping of CCND1 and 
MYC [46]. An RNA element was identified that 
conferred increased capping activity when fused to 
a LacZ reporter upon eIF4E overexpression; this 
element is referred to as a Cap Sensitivity Element 
(CapSE) [9]. LacZ-CapSE transcripts were not 
enriched in eIF4E RIPs relative to LacZ fusion 
RNAs suggesting that eIF4E was not directly 
involved in recognition of this element. However, 
LacZ-CapSE was enriched in RNMT IPs relative to 
LacZ, supporting a role for RNMT in CapSE 
recognition. We note that it does not appear that 
eIF4E overexpression simply provides protection 
against decapping by directly binding to m7G caps 
of target RNAs [9]. In support of this, eIF4E over-
expression increased capping of some RNAs that 
were not found in eIF4E nuclear RIPs; moreover, 
while eIF4E interacted with LacZ-4ESE RNAs in 
nuclear RIPs, these did not undergo increased 
capping upon eIF4E overexpression [9]. Thus, 
eIF4E elevates the capping of many RNMT cap-
ping targets and it does not need to directly 
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interact with these RNAs in the nucleus for this to 
occur. This suggests that at least for some RNAs, 
the impact of eIF4E on capping is via its ability to 
increase RNMT, RAM and RNGTT protein levels.
Despite their global importance, little is known 
about the factors that regulate the production of 
the capping machinery. Overexpression of eIF4E 
in model systems elevates nuclear RNA export for 
endogenous RNGTT, RAM and RNMT (and thus 
increased levels of these RNAs in the cytoplasm) 
and additionally increases the number of ribo-
somes per transcripts, i.e. improves translational 
efficiency, for RNGTT and RNMT [9]. This leads 
to elevated levels of these proteins upon eIF4E 
overexpression. By contrast, CRISPR-4E cells 
have reduced levels of these proteins relative to 
CRISPR control cells [9]. eIF4E provides the first 
example of a factor that controls the levels of the 
capping machinery. As described above, this is 
related to the increased capping activity observed 
for selected RNAs by eIF4E.
Modulation of capping in cancer, 
differentiation and development
Regulation of capping enzymes expression has an 
important role in cell differentiation [12]. Levels of 
the RNMT-RAM complex are high in embryonic 
stem cells, and this elevation is required for the 
expression of pluripotency associated genes [12]. 
During differentiation, ERK1/2 phosphorylates 
RAM, targeting it for degradation. This results in 
repression of pluripotency-associated genes and is 
required for differentiation to occur. Conversely, 
expression of RNMT-RAM in fibroblasts enhances 
the efficiency of reprogramming, probably due to 
its impact on these pluripotency-associated genes.
Capping can be dysregulated in cancer in pri-
mary specimens and cell line models. One such 
example comes from eIF4E where capping was 
elevated in high-eIF4E acute myeloid leukemia 
(AML) patient specimens compared to blood 
cells from healthy volunteers [60–62]. In these 
patient specimens, there was elevated capping of 
coding and non-coding transcripts (MALAT, 
RNMT, MYC) by ~2-3 fold relative to healthy 
volunteers using CapIP methods [9]. Further, 
there were elevated protein levels for RNGTT 
and RNMT in these patient specimens [9]. By 
contrast, capping of other RNAs such as 
ACTNB or POLR2A were the same in AML 
patients versus healthy volunteers, consistent 
with their insensitivity to eIF4E overexpression 
in model systems. Transcripts were normalized to 
corresponding total RNA levels and thus differ-
ences in RNA levels do not account for changes 
in levels of capping [9]. These studies were the 
first to show that capping can be dysregulated in 
primary cancer specimens [9]. eIF4E overexpres-
sion is known to increase transformation, this is 
attributed to its roles in RNA export and transla-
tion [55,63], but it seems likely that this could 
include capping as well. Consistent with the 
interplay between RNMT and eIF4E, genetically 
engineered RNMT overexpression increased cap-
ping efficiency of specific transcripts (CCND1 
and MYC) increasing their protein levels with 
no changes in total mRNA levels [46]. Through 
this activity, RNMT overexpression oncogenically 
transforms mammary epithelial cell lines in cul-
ture [46].
The increased dependency of subsets of genes 
on high levels of capping enzymes is important 
when considering therapeutic targeting. The genes 
most and least dependent on RNMT, for example, 
will influence the cellular response to its inhibi-
tion. In a panel of breast cancer cell lines, RNMT 
inhibition was observed to selectively inhibit the 
proliferation of cell lines expressing oncogenic 
PI3KCA mutants [64]. This implies that a subset 
of genes induced by PI3KCA are dependent on 
RNMT for expression, and/or that the most 
RNMT-dependent genes are required in PI3KCA 
oncogene-addicted cells [64]. MYC oncogene 
expression has enhanced dependency on RNGTT, 
including dysregulated MYC [65]. This depen-
dency may be a function of the high turnover of 
Myc protein and RNA. MYC and N-Myc upregu-
late capping by promoting RNA polymerase II 
phosphorylation, which increased recruitment of 
the capping enzymes to specific genes [10,48,65], 
as well as increased expression of S-adenosyl 
homocysteine hydrolase (SAHH), which neutra-
lizes the inhibitory SAH bi-product of methylation 
reactions [66].
Other oncogenic factors also regulate the cap-
ping machinery e.g. Wnt and CDK1 [67]. For 
example, CDK1 increases cap methylation by 
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phosphorylating the RNMT regulatory domain; 
this has a gene-specific impact, although what 
governs specificity in this case is unclear and the 
mechanism may involve recapping [13].
Recapping of RNAs after decapping
In the early 1990s, the Maquat laboratory found 
that cytoplasmic β-globin RNAs were apparently 
re-capped after fragmentation that provided new 
5' ends [8]. Indeed, 5' truncated forms of β- 
globin bind equally well to the cap-antibody 
and to eIF4E as do the parent transcripts [6,8]. 
The truncated forms were restricted to the cyto-
plasm [6]. This suggested that capping is not 
restricted to co-transcriptional events but also 
occurs post-transcriptionally in mammalian 
cells [6,8,14,31]. Indeed, it appears that capping 
can occur both in the nucleus and cytoplasm. 
RNMT, RAM and RNGTT are all found in the 
cytoplasm, albeit at lower levels at steady state 
than in the nucleus [6,14,31]. The likely sub-
strates for recapping would be RNAs that have 
had their caps removed by the decapping 
enzymes DCP1/DCP2 or DCPS or transcripts 
that have undergone internal endonuclease clea-
vage [32,68]. Of interest, 5' decay is slow and 
inefficient relative to 3' decay providing support 
for the ability to have a pool of RNAs ready to 
be recapped [69]. In support of this, cap home-
ostasis is independent of polyA tail length [70]. 
For many RNA substrates, 5'decapping leaves 
RNAs with 5'-monophosphate, and thus need 
a kinase in order to convert to the 5'- 
diphosphate which is a substrate of RNGTT. 
Such a kinase has been identified as a RNGTT 
co-factor [6] and some decapping enzymes leave 
a 5'-diphosphate which produce suitable sub-
strates for RNGTT (e.g. Nudt12, Nudt15, 
Nudt2 and Nudt3) [32].
Cytoplasmic recapping on a genome-wide 
scale has been observed through the use of 
cellular fractionation and XRN sensitivity 
assays which identify RNAs without a 5' pyro-
phosphate linkage [14]. In one study, XRN sen-
sitivity was complemented with 5' RACE 
methods as well as exclusion of uncapped 
RNAs from cap affinity chromatography (com-
prised of eIF4E-GST bound to eIF4G to 
increase its affinity for the m7G cap) with all 
three methods yielding concordant results [14]. 
These studies suggested that about 1000 tran-
scripts were uncapped using microarray meth-
ods with a ~ 2–5-fold enrichment in uncapped 
RNAs upon overexpression of an RNGTT 
mutant (K294A). In these studies, which focus 
on cytoplasmic RNAs, it was observed that the 
uncapped RNAs were sequestered from poly-
somes suggesting that they were maintained in 
an inactive state as a regulatory feature [14]. 
RNAs that were recapped were enriched in 
AREs in their 3' UTR [14]. There are several 
advantages for cytoplasmic or nuclear re- 
capping. In the cytoplasm, uncapped RNAs 
could be stored in an uncapped state and then 
re-imported into the active translation pool 
[14] (Figure 3). Given all the necessary enzymes 
are present, nuclear recapping is also theoreti-
cally possible. In this way, transcripts can be 
stored in “stasis” waiting for further processing 
and export to the cytoplasm. In both cases, 
RNAs could be released through signaling 
events that would enable processes such as 
RNA export to the cytoplasm or reentry into 
the active translation pool (Figure 3).
Perspectives and conclusions
Analogies to other RNA processing events furnish 
examples of decoupling RNA processing steps such 
as capping from transcription. For instance, similar 
to capping discussed above, splicing as well as 3' 
cleavage and polyadenylation (CPA) occur co- 
transcriptionally and/or post-transcriptionally. 
Indeed, RNAs can be partially processed, stored 
and then reenter the active transcript pool. This 
leaves RNAs in “stasis” until they are required for 
action rendering an elegant level of control that 
avoids the needs of further rounds of transcription 
and allows for fine-tuning of the composition of the 
final RNA product. For instance, CTN RNAs are 
stored in the nucleus after CPA [35]. Upon certain 
types of stress, these RNAs undergo a second CPA 
step producing a transcript variant known as CAT2 
mRNA which is exported to the cytoplasm and 
translated into the CAT2 protein [35]. Similarly, 
RNAs with detained introns remain in the nucleus 
until they are required [33,34]. Indeed, the same 
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RNA can undergo co-transcriptional splicing for 
some introns, followed later by post-transcriptional 
splicing for other introns [34]. Studies reviewed 
here reveal a parallel strategy, whereby cells produce 
RNAs at steady state which have reduced percen-
tage capping or even different types of caps. 
Dynamic m7G capping is demonstrated for specific 
RNAs upon overexpression of certain factors, for 
example, eIF4E, Myc, RNMT, or at particular devel-
opmental and differentiation stages. Capping can 
occur in either compartment, where in the cyto-
plasm it can be used to titrate the translation capa-
city of specific RNAs based on current cellular 
requirements. Alternatively, or indeed contempora-
neously, uncapped RNAs could be trapped in the 
nucleus to await further processing and/or because 
uncapped RNAs are poor export substrates (Figure 
3). There are multiple proteins that bind the cap 
and initiate cap-dependent translation for selected 
transcripts e.g. eIF4E, eIF4E2, eIF4E3, eIF3d, CBC, 
and PARN [71]. Thus, the capacity of eIF4E to 
increase capping could provide more substrates for 
its direct role in RNA export and/or translation, or 
by furnishing substrates for other cap-binding pro-
teins. Other forms of the 5' cap can also be sensitive 
to cellular signals such as NAD capping can flux 
based on nutrient conditions [32,72]. Keeping 
RNAs in stasis is an efficient means to conserve 
energy in the cell, and allows for rapid responses to 
changes in the cellular environment. Capping could 
be coordinately regulated for groups of RNAs act-
ing in the same biochemical pathway, for example, 
RNA regulons. Selection of groups of RNAs for 
regulation by capping appears to be driven by cis- 
acting elements in the RNA such as the CapSE, 
AREs, sORFs, pseudoknots, introns and likely 
others [7,9,14]. In all, cap dynamics is positioned 
to provide sensitive control mechanisms to tune the 
proteome in response to biological situations.
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